Foundayo's FDA Approval Letter Shows an Unusually Long List of Required Safety Studies

Eli Lilly's orforglipron, sold as Foundayo, was approved by the FDA on April 1, 2026 under application number 220934 for chronic weight management in adults with obesity, and in adults with overweight who also have at least one weight-related condition.

It is the first small-molecule GLP-1 receptor agonist approved for weight loss, meaning it is a conventional pill rather than a peptide, with no fasting or water restrictions around dosing.

In mid-April, reporters worked through the approval letter that the FDA posts alongside every approval, and the picture it painted got more attention than the approval itself. The letter sets out what the agency still wants answered now that the drug is on the market.

According to reporting by BioPharma Dive, Fierce Pharma and others who read the letter, the FDA concluded that only a clinical trial would be adequate to evaluate a signal of serious risk involving retained stomach contents, and to look for unexpected serious risks of major adverse cardiovascular events, drug-induced liver injury, and exposure through breast milk.

The requirements described in that coverage include: using Lilly's ACHIEVE-4 cardiovascular outcomes trial to supply data on heart attacks, strokes and other cardiovascular events, plus liver findings such as unexplained enzyme elevations, cases meeting Hy's law criteria, and discontinuations for liver-related reasons; a clinical pharmacology study testing what happens when doses are withheld and when patients fast, intended to inform advice for reducing the risk of pulmonary aspiration in people with delayed stomach emptying; a milk-only lactation study measuring how much orforglipron reaches breast milk; a pregnancy exposure registry; a registry following children with obesity who use weight-loss drugs; at least 15 years of follow-up on thyroid cancer, consistent with the class boxed warning about thyroid C-cell tumors; and enhanced pharmacovigilance for drug-induced liver injury for five years after approval, with expedited reporting of serious cases.

BioPharma Dive reported that ACHIEVE-4 was due to finish in April 2026, with results going to the FDA by July 2026. Lilly said the requirements match the agency's normal approach to newly approved medicines and that no liver safety signal had been seen across the Phase 3 program. In data the company released in mid-April, ACHIEVE-4 showed cardiovascular safety that was non-inferior to insulin glargine, with a 16% lower observed rate of major adverse cardiovascular events, and 8.8% average weight reduction versus a 1.7% gain on insulin.

The required studies frame practical monitoring questions

If you are considering Foundayo or already taking it, this is worth understanding as context rather than alarm. Postmarketing requirements are routine, and every GLP-1 on the market carries some. What is notable here is the breadth and length of the list, which reflects that orforglipron is a brand new chemical rather than a variation on an ingredient with a decade of human data behind it.

The practical items to discuss with your clinician are the ones tied to real situations: pregnancy or trying to conceive, breastfeeding, upcoming surgery or anesthesia where delayed stomach emptying and aspiration risk come up, a personal or family history of medullary thyroid carcinoma, and any symptoms suggesting liver trouble. Those are the exact questions the FDA has told Lilly to study, which makes them reasonable questions to raise now.

Required studies do not prove harm

None of this says Foundayo has been shown to cause liver injury, heart problems, or thyroid cancer. The FDA's language describes risks it wants ruled out, not risks it has confirmed. Approval means the agency judged benefits to outweigh known risks for the approved population. The 16% lower cardiovascular event rate reported by Lilly comes from a trial designed to demonstrate safety rather than superiority, and an observed difference in that setting is not proof of benefit. The details enumerated above come from journalists reading the posted approval letter; the letter itself is the authoritative text and is linked below. A required study is also not a recall, a warning update, or a reason to stop a medication without talking to your prescriber.